

Supplemental Table 1a. Lung function in percent of predicted at 19 years in the post-bronchiolitis group compared to the control group. Results from mixed effects linear regression analyses including calculations of predictive margins.

		N	Effect estimate		Predictive margin (95% CI)	
			β (95% CI)	P-value*	Post-bronchiolitis	Control
FVC	% of predicted ^a	342	-0.01 (-0.03, 0.01)	0.350	100.4 (98.7, 102.0)	101.5 (99.6, 103.3)
	% of predicted ^b	306	-0.01 (-0.03, 0.02)	0.586	100.5 (98.7, 102.2)	101.1 (99.3, 103.0)
FEV₁	% of predicted ^a	341	-0.04 (-0.06, -0.01)	0.004	95.5 (93.9, 97.1)	99.2 (97.3, 101.0)
	% of predicted ^b	305	-0.04 (-0.06, -0.01)	0.005	95.3 (93.5, 97.1)	99.0 (97.1, 100.9)
FEV₁/FVC	% of predicted ^a	341	-0.03 (-0.04, -0.01)	0.002	94.4 (93.4, 95.5)	97.0 (95.8, 98.3)
	% of predicted ^b	305	-0.03 (-0.05, -0.01)	<0.001	94.1 (92.9, 95.2)	97.2 (95.9, 98.4)
FEF₂₅₋₇₅	% of predicted ^a	341	-0.08 (-0.12, -0.03)	0.001	86.0 (83.2, 88.9)	93.6 (90.3, 96.9)
	% of predicted ^b	305	-0.08 (-0.13, -0.04)	<0.001	85.3 (82.2, 88.3)	93.6 (90.3, 96.9)

Abbreviations: CI = confidence interval; β = regression coefficient comparing the post-bronchiolitis group to the control group; FVC = forced vital capacity; FEV₁ = forced expiratory volume in first second; FEF₂₅₋₇₅: forced expiratory flow between 25-75% of the forced vital capacity.

The predictive margins are products of the regression analyses and correspond to the predicted mean values of the outcomes if everyone had a previous history of bronchiolitis, or if everyone had no history of bronchiolitis, with all other covariates kept at their original value.

* P-values for β from Wald test. Bold values denote statistical significance at the P < 0.05 level.

^a Unadjusted model.

^b Adjusted for birthweight, gestational age at birth, household smoking ever, atopic dermatitis, family history of atopy.

Supplemental Table 1b. Lung function in percent of predicted at 19 years after RSV bronchiolitis compared to non-RSV bronchiolitis. Results from mixed effects linear regression analyses including calculations of predictive margins.

		N	Effect estimate		Predictive margin (95% CI)	
			β (95% CI)	P-value*	RSV	Non-RSV
FVC	% of predicted ^a	164	-0.02 (-0.06, 0.02)	0.282	99.3 (97.1, 101.4)	101.3 (98.3, 104.4)
	% of predicted ^b	139	-0.03 (-0.07, 0.01)	0.134	98.7 (96.3, 101.1)	101.8 (98.5, 105.1)
FEV₁	% of predicted ^a	164	-0.00 (-0.04, 0.04)	0.923	94.8 (92.5, 97.1)	95.0 (91.8, 98.2)
	% of predicted ^b	139	-0.00 (-0.05, 0.04)	0.898	94.4 (91.9, 97.0)	94.7 (91.2, 98.3)
FEV₁/FVC	% of predicted ^a	164	0.02 (-0.01, 0.04)	0.131	94.8 (93.4, 96.3)	92.9 (90.8, 94.9)
	% of predicted ^b	139	0.03 (0.00, 0.06)	0.038	95.0 (93.4, 96.6)	92.1 (90.0, 94.3)
FEF₂₅₋₇₅	% of predicted ^a	164	0.03 (-0.03, 0.10)	0.317	86.3 (82.4, 90.2)	82.9 (77.3, 88.4)
	% of predicted ^b	139	0.05 (-0.02, 0.12)	0.179	86.3 (82.0, 90.5)	81.3 (75.4, 87.1)

Abbreviations: RSV = respiratory syncytial virus; CI = confidence interval; β = regression coefficient comparing the RSV group to the non-RSV group; FVC = forced vital capacity; FEV₁ = forced expiratory volume in first second; FEF₂₅₋₇₅ = forced expiratory flow between 25-75% of the forced vital capacity;.

The predictive margins are products of the regression analyses and correspond to the predicted mean values of the outcomes if everyone had a previous history of RSV bronchiolitis, or if everyone had a history of non-RSV bronchiolitis, with all other covariates kept at their original value.

* P-values for β from Wald test. Bold values denote statistical significance at the P < 0.05 level.

^a Unadjusted model.

^b Adjusted for birthweight, gestational age at birth, household smoking ever, atopic dermatitis, family history of atopy.